We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+60.37%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.46B
AUM Growth
+$766M
Cap. Flow
-$98.5M
Cap. Flow %
-2.85%
Top 10 Hldgs %
44.87%
Holding
104
New
18
Increased
30
Reduced
19
Closed
12

Top Buys

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$55.7M
2
CELC icon
Celcuity
CELC
+$53M
3
ROIV icon
Roivant Sciences
ROIV
+$50M
4
PEN icon
Penumbra
PEN
+$47.4M
5
MRUS
Merus
MRUS
+$42M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$520M
2
SLNO
Soleno Therapeutics
SLNO
+$36.1M
3
AORT icon
Artivion
AORT
+$29.2M
4
BBNX
Beta Bionics
BBNX
+$23.1M
5
EOLS icon
Evolus
EOLS
+$22.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.69%
2 Miscellaneous 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VKTX icon
76
Viking Therapeutics
VKTX
$4.07B
$2.78M 0.08%
105,597
-275,103
-72% -$8.21M
PYXS icon
77
Pyxis Oncology
PYXS
$324M
$2.62M 0.08%
+1,178,307
New +$1.7M
LONA
78
LeonaBio Inc
LONA
$71.2M
$2.24M 0.06%
540,296
– –
SPRY icon
79
PUT
ARS Pharmaceuticals
SPRY
$559M
$2.01M 0.06%
+200,000
New +$2.87M
TRIB
80
Trinity Biotech
TRIB
$7.65M
$1.86M 0.05%
59,667
– –
AVTX icon
81
Avalo Therapeutics
AVTX
$1.03B
$1.78M 0.05%
139,667
– –
NVNO
82
enVVeno Medical
NVNO
$7.95M
$1.59M 0.05%
50,258
+13,545
+37% +$1.38M
LYRA
83
DELISTED
LYRA THERAPEUTICS INC
LYRA
$1.5M 0.04%
229,382
-25,768
-10% -$189K
QURE icon
84
uniQure
QURE
$3.09B
$1.17M 0.03%
+20,000
New +$363K
LXEO icon
85
Lexeo Therapeutics
LXEO
$401M
$929K 0.03%
139,835
– –
BDSX icon
86
Biodesix
BDSX
$276M
$821K 0.02%
108,694
– –
ANRO icon
87
Alto Neuroscience
ANRO
$1.4B
$625K 0.02%
+155,366
New +$515K
APYX icon
88
Apyx Medical
APYX
$128M
$321K 0.01%
150,000
– –
ENSC icon
89
Ensysce Biosciences
ENSC
$8.87M
$205K 0.01%
86,666
– –
RVMDW icon
90
Revolution Medicines Inc Warrant
RVMDW
$129M
$75K ﹤0.01%
250,000
– –
SRZNW
91
DELISTED
Surrozen Inc Warrant
SRZNW
$2.97K ﹤0.01%
166,666
– –
CAPR icon
92
CALL
Capricor Therapeutics
CAPR
$547M
– –
-100,000
Closed -$993K
CAPR icon
93
PUT
Capricor Therapeutics
CAPR
$547M
– –
-650,000
Closed -$6.45M
CRL icon
94
Charles River Laboratories
CRL
$13.8B
– –
-100,000
Closed -$15.2M
EOLS icon
95
Evolus
EOLS
$614M
– –
-2,474,843
Closed -$22.8M
FBRX
96
DELISTED
Forte Biosciences
FBRX
– –
-68,192
Closed -$882K
GMED icon
97
Globus Medical
GMED
$10.5B
– –
-88,500
Closed -$5.22M
KALA icon
98
KALA BIO
KALA
$9.81M
– –
-1,105
Closed -$263K
PODD icon
99
Insulet
PODD
$10.2B
– –
-60,387
Closed -$19M
RARE icon
100
Ultragenyx Pharmaceutical
RARE
$1.51B
– –
-270,000
Closed -$9.82M
1 2 3
4
5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q3 2025 Portfolio in Review

As of Q3 2025, Perceptive Advisors held 104 positions worth $3.46B, up 28% from $2.7B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Perceptive Advisors's Q3 2025 filing shows 18 new, 30 increased, 19 reduced and 12 closed positions. Its largest new stake was Abivax: 388,608 shares worth $33M. The largest sale was Verona Pharma, an estimated $520M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

  • Perceptive Advisors's largest Q3 2025 buy was Abivax: 388,608 shares worth $33M.
  • Perceptive Advisors added most to Travere Therapeutics in Q3 2025, an estimated $55.7M increase.
  • Perceptive Advisors's biggest Q3 2025 reduction was Verona Pharma, cutting an estimated $520M.
  • Perceptive Advisors fully exited Soleno Therapeutics in Q3 2025, selling an estimated $36.1M.
  • Perceptive Advisors's ten largest holdings make up 45% of its $3.46B portfolio in Q3 2025.
  • Perceptive Advisors opened 18 new positions and closed 12 in Q3 2025.
  • Perceptive Advisors's portfolio value rose 28% quarter-over-quarter to $3.46B.

Based on Perceptive Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.